Financings
| Company Name | Amount Raised | Type of Fundraise | Country | Date |
| Private company financings | ||||
| AdvanCell | $112 million | Series C | Australia | 3 February |
| Latent Labs | $50 million | Seed | UK | 12 February |
| Abcuro | $200 million | Series C | US | 12 February |
| Junevity | $10 million | Seed | US | 12 February |
| Latent Labs | $50 million | Series A | US | 13 February |
| Bambusa Therapeutics | $90 million | Series A | US | 14 February |
| Atrandi Biosciences | $25 million | Series A | Lithuania | 18 February |
| EG 427 | $28 million | Series B | France | 20 February |
| Achira | $33 million | Seed | India | 21 February |
| Eikon Therapeutics | $351 million | Series D | US | 26 February |
| Public company financings | ||||
| Annovis Bio | $21 million | CMPO | US | 3 February |
| GH Research | $150 million | Follow-on fundraise | Ireland | 4 February |
| Sionna Therapeutics | $219 million | IPO | US | 7 February |
| Atai Life Sciences | $55 million | CMPO | Germany | 12 February |
| Aardvark Therapeutics | $100 million | IPO | US | 13 February |
| InflaRx | $30 million | CMPO | Germany | 13 February |
| Oculis Holding | $100 million | RD | Switzerland | 13 February |
| Arcus Biosciences | $150 million | RD | US | 18 February |
| Solid Biosciences | $200 million | RD | US | 18 February |